Managing Post-Approval Changes in a Global Environment: The Case for Product-Based Impact Assessments

Jenifer Avenatti, Baxter Healthcare

As regulatory agencies push industry toward risk management and product design space knowledge, how can organizations with global products manage change control in a robust and efficient way? The answer to this question is multifaceted but certainly achievable.

Cover Art Illustrated by Katja Yount

Regulation

34 Regulatory Snapshot: Interest Group Corner: Interactive “Speed Dating” Leads to Intense Discussion on Key Inspection Topics
35 Divergent Approaches to Stem Cell Regulation
39 GMP Oversight of Medicines Manufacturers in the EU

Voices of PDA

42 President’s Message: PDA Enters 2016 on High Note
44 Voices of the Board: 2020 Strategic Plan Offers Guidance in Changing Times
46 Editor’s Message: Success: The PDA Letter’s New Online Home

News & Notes

6 2016 Board of Directors
7 2020 Strategic Plan Released

People

8 PDA Volunteer Spotlight: Morten Munk
10 Chapter Update: Chapter Tours United Airlines Cold Chain Cargo Facility
11 Chapter Update: Experts Underscore Key Role of Data Integrity
12 PDA Photostream: 10th Annual Global Conference on Pharmaceutical Microbiology

Science

16 Science Snapshot: Making Visual Inspection of Opaque Product Less Cloudy;
Journal Preview: Container Closure Topics Explored in Latest Issue of the PDA Journal
18 PDA ConnectSM: Visual Inspection as Part of a Stability Program
When it comes to the global post-approval management process, procedural and administrative differences are unavoidable per se in view of the various legal and political systems in the different regions of the world. Yet, simplification and harmonization could potentially reduce administrative burden. To illustrate the regulatory administrative hurdles faced within the European Union alone, the procedure/process for transferring a marketing authorization (MA)—also referred to as a change in ownership of an MA—is one example where harmonization of administrative procedures could significantly reduce the burden for both industry and regulatory agencies.

PDA volunteers Leticia Quinones and Cecilia Turoff provide their perspectives on the first and second days of the 2015 PDA/FDA Joint Regulatory Conference.

When it comes to post-approval changes, it can seem like jumping through a series of challenging hoops, especially due to the globalization of the industry. Ultimately, all this can impact the reliable supply of product for the patient.
Four Steps to Modernizing Aging Control Systems
Timothy Miller and Andy Miller, Xellia Pharmaceuticals USA

Obsolete manufacturing control systems are one of the challenges typically encountered in aging pharmaceutical facilities. Often, the control systems become outdated well in advance of the process or equipment it controls. When this is the case, upgrading the control system can be as complicated and expensive as replacing the manufacturing system itself. That is why an effective strategy for upgrading or replacing control systems is important.

Cover Art Illustrated by Shutterstock

Departments

News & Notes

6  FDAers Offer Agency Perspectives at Annual Meeting
7  New Annual Report Explains How Members “Lead the Way”

People

8  PDA Volunteer Spotlight: Lucy Cabral
10  Chapter Update: Chapter Seminar Explores Aseptic Manufacturing Concerns
11  Make Memories at the 2016 PDA Annual Meeting
12  Tools For Success: The 20-Point Job Search Game Plan

Science

14  Science Snapshot: Meeting Preview: Interest Group Schedule; PDA Journal Top 10: Data Integrity Case Study Tops Most-Read PDA Journal Articles for December
15  Don’t Be a Daredevil When Retrofitting Your Facility
17  Keep Your Facility Up-to-Date in a Complex Market
18  PDA Connect™: The Future of the Glass Ampoule

Regulation

33  Regulatory Snapshot: Meeting Preview: Interest Group Schedule
35  Quality Risk Management Meets Aging Facilities
36  GMP Oversight of Medicines Manufacturers in the EU
40  Annex 1 Update: What Does it Mean for Industry?
43  Regulatory Briefs

Voices of PDA

44  Voices of the Board: Think “Facility,” “Process” and “Analytics” When Updating Your Aging Manufacturing Site
46  Editor’s Message: Old Facilities Don’t Enjoy Many Happy Returns
Contents

Features

28 Older Pharmaceutical Factories – What Does FDA Say?
Thomas Peither, Maas & Peither AG
Older factories can indeed exemplify the state of the art. This was the opinion expressed by Sharon Thoma of the U.S. FDA at the PDA Annual Meeting in March 2015.

30 Signs Your Facility Might Need an Upgrade
What are some signs that your facility is aging and requires upgrades? Find out in this issue’s infographic.
The pharmaceutical industry is at the cutting edge in terms of types of products and technologies offered and under development. The last 30 years has seen the biopharm boom, and most recently, the marriage of cutting-edge therapies with high-tech delivery systems, particularly prefilled syringes and other injection devices. The industry is moving into new areas of advanced therapies with personalized medicine, stem cells, nanotech and 3-D printing (in fact, the U.S. FDA approved the first 3-D printed pill last year).

Photo courtesy of Jens Liebchen. Representatives from Bausch + Ströbel showcase the company’s VarioSys machine at the 2015 Universe of Pre-filled Syringes and Injection Devices.
Features

28 Survey of Industry Leachables Best Practices Completed
BPPOG Disposables Team Shares Results

Over the past five years, the use of disposable systems/equipment (aka single-use systems) in biopharmaceutical manufacturing processes has reached a pivotal point. Disposables are being implemented beyond research and development and are now being used in clinical and commercial manufacturing. The benefits of disposables are well known and publicized. A 2014 article in the PDA Journal of Pharmaceutical Science and Technology outlined a number of advantages, including lower initial capital investment, elimination of cleaning validation, reduced turnaround time, reduced cross-contamination, reduced steam sterilization burden and operations, the possibility of reducing room classification, and the ability to scale up and down.

32 The Future of Manufacturing

As new solutions and technologies enter the market, manufacturing will certainly see significant changes over the next ten years. To get a sense for what these flavors might be like, we asked some long-time PDA volunteers the question: “What technology do you believe will revolutionize pharmaceutical manufacturing in the next 10 years?”

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.
Virus Retentive Filtration in Biopharmaceutical Manufacturing
Dayue Chen, PhD, Eli Lilly and Company, and Qi Chen, PhD, Genentech

Virus removal using retentive filters designed to provide effective and consistent clearance of parvovirus (~20 nm) has now become an established standard in downstream purification processes for biologics produced using mammalian cells. Compared to other commonly used virus clearance methods, such as chromatography and low pH inactivation, retentive filtration is superior in its ability to clear almost all potential viral contaminants while also avoiding adverse effects on product quality. While commercially available retentive filters vary in chemical composition and structural configuration, all of these filters primarily clear viruses through the mechanism of size exclusion.

Photo courtesy of Pall Corporation. Copyright Pall Corporation 2016
Missed Opportunities for Adventitious Agents Testing
Sven M. Deutschmann, PhD, Roche Diagnostics GmbH

Current adventitious agent test methods feature numerous limitations. Assays based on polymerase chain reaction (PCR) offer the potential to lift these limitations and offer better overall detection of adventitious agents. This is an area that biologics manufacturers are actively exploring, and current research indicates that PCR-based testing is not only scientifically valid but also acceptable to regulators.

The “Usual Suspects” of Viral Contamination
Biopharmaceutical manufacturing utilizes cell lines from living organisms. These cell lines can be contaminated with viruses. This issue’s InfoGraphic offers some examples of viruses that have contaminated cell lines in biologics manufacturing.

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.
Big Data Meets Vaccine Manufacturing
Rebecca Stauffer, PDA

Since the late 2000s, “Big Data” has become a buzzword used throughout various industries. The term itself refers to datasets “so large and complex that they become awkward to work with using standard statistical software” \(^1\). Big Data is about more than just the collection of data. It’s about using it to make decisions based on efficient analysis. Making sense of it is the challenge facing most companies. But companies are solving this challenge and taking specific actions based upon the information gained.

\(^1\) Reference: Source, p. 1.
The Dangers of Underestimating Method Variability
Nanda Subbarao, Biologics Consulting

As a consultant, I have personally observed how method variability is often underestimated in pharmaceutical laboratories. This can lead to misinterpretations of data presented in the CMC. Such underestimations of variability should not occur in laboratories with robust overarching quality systems that cover all facets of a pharmaceutical laboratory’s operations. Yet, in practice, I have seen quality systems breakdown for various reasons during routine laboratory operations, mostly due to limitations of time and resources.

The Economics of Vaccines
This issue’s Infographic showcases some economic facts about vaccines.
A Line of Sight Approach for Assessing Aseptic Processing Risk
Hal Baseman, Marsha Hardiman, Walter Henkels and Mike Long, ValSource

Aseptic processing of sterile drug products can and should be improved. The same challenges, problems and issues seem to appear, reappear, or never really disappear from year to year. These problems persist despite more awareness of the issues due to increased training, conference sessions on the topic, guidance documents, quality system management approaches and metrics. Each year, regulatory audit observations, 483s, and warning letters continue to cite the same problems and issues over and over. Admittedly, aseptic processing is challenging and there are obstacles to improvement, but it is the job of those working in this area to resolve these challenges.
Features

30  7 Steps for a Reproducible Cycle Development Plan
Stefan Kleinmann PhD, Matthias Scheu, Christian Fecht, METALL+PLASTIC

Decontamination cycle development takes place between the completed operational qualification and the subsequent process validation. It also determines the parameters for a successful, effective and repeatable decontamination process that complies with the requirements of both regulatory agencies and end users. The PIC/S guide for isolators states that an isolator decontamination cycle using a minimum 6-log spore reduction is often applied. During routine operation, pharmaceutical isolators and material transfer chambers use decontamination cycles to yield a theoretical 10- to 12-log spore reduction for additional safety.

34  Is the Sterility Test Holding Your Batches Hostage?
Find out how you can liberate your terminally sterilized batches with parametric release.
Cover

PDA Celebrates 25 Years of Industry, FDA Collaboration
Take a step back and revisit some PDA/FDA Joint Regulatory Conferences of yesteryear!

Cover Art Illustrated by Caroline Cruz Design

Departments

News & Notes

6 PDA HQ Moves, TRI Opens New Lecture/Lunch Rooms
7 25 for 25: Silver Anniversary Draws 25+ FDA Speakers

People

8 Volunteer Spotlight: Andrew C. Chang, PhD
10 Tales from the Trail: Speakers Offer EM Insights at Chapter Symposium
12 Photostream: 2016 PDA Biosimilars Conference
13 Make New Connections at the 2016 PDA/FDA JRC

Science

14 Science Snapshot: Meeting Preview: Interest Group Meeting Schedule; Surveys Says...Check Out PDA’s Portfolio of Surveys; SAB Supports PDA Interest Group Initiative; Journal Preview: July/August Issue of PDA Journal Explores the Latest Research on CCIT, Virus Filtration, Packaging and More
16 Technology Column: Another Step Toward Injection-Free Drug Delivery
18 Are You Prepared for the Industry’s Transformation?
20 PDA Summer Reading
25 The Future is “Cloudy” for Data Integrity
27 Keeping Current with Industry Trends and Emerging Technology

Regulation

48 Regulatory Snapshot: Meeting Preview: Interest Group Meeting Schedule
49 Back to the Future
51 Applying QRM to the Change Control Process
54 Workshop Offers DI Insights from Regulator, Industry
55 Client/CMO Partnership starts with the Quality Agreement

Voices of PDA

56 Voices of the Board: Assuring Data Integrity
58 Editor’s Message: A First in Europe; A First and 25th in USA
Contents

Features

32 How to Avoid a Data Integrity Citation
Brad Mercer, Mylan, Deborah Autor, Mylan, Zena Kaufman, ZGK Quality Consulting
One specific topic continues to draw extensive regulatory attention, including numerous citations in U.S. FDA Warning Letters: data integrity.

39 What Recent FDA Warning Letters Can Teach Us
Zena Kaufman, ZGK Consulting
Data integrity emerged as a common theme following a review of six recent U.S. FDA Warning Letters.

42 A Line of Sight Approach for Assessing Aseptic Processing Risk
Hal Baseman, Marsha Hardiman, Walter Henkels and Mike Long, ValSource
In this article, the authors present examples of how REM can be used to evaluate aseptic process interventions.

46 4 Ways to Ensure Data Integrity
Find out how your company can better ensure its data integrity in this issue’s infographic.

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.

Executive Staff

Richard Johnson
President
Craig Elliott
Sr. VP, Education
Jennifer Bell
VP, Finance
David Hall
VP, Sales
Rich Levy, PhD
Sr. VP, Scientific & Regulatory Affairs
Wanda Neal
Sr. VP, Programs and Registration Services
Georg Roessling, PhD
Sr. VP, PDA Europe

PDA’s Mission
To develop scientifically sound, practical technical information and resources to advance science and regulation for the pharmaceutical and biopharmaceutical industry through the expertise of our global membership

PDA’s Vision
To be the foremost global provider of science, technology, and regulatory information and education for the pharmaceutical and biopharmaceutical community

PDA Board of Directors

Officers
Chair: Martin VanTrieste
Chair-Elect: Rebecca Devine, PhD Regulatory Consultant
Treasurer: Michael Sadowski, Baxter Healthcare
Secretary: Jette Christensen, Novo Nordisk
Immm. Past Chair: Harold Baseman, ValSource

Directors
Masahiro Akimoto, Otsuka Pharmaceutical Factory, Inc.
Joyce Bloomfield, Novartis
Veronique Davoust, Pfizer
Anil Sawant, Merck

Deborah M. Autor, Mylan
Ursula Busse, PhD
Emma Ramnarine, Genentech/Roche
Melissa Seymour, Biogen

Stephan Rönninger, Amgen
Anil Sawant, Merck
Melissa Seymour, Biogen

John Shabushinig, PhD, Insight Pharma Consulting, LLC
Glenn Wright, Eli Lilly and Company

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.
Heads or Tails: Statistical Methods for Interpreting Multiple Biological Indicator Results
Donald Eddington, PhD, Eddington and Bond Associates, Inc.

One of the main advantages of using an isolator for an aseptic processing application is that it creates a physical separation between the operator and the aseptic workspace. Another main advantage is that an isolator can be completely sealed before aseptic work begins, allowing for the exposed interior surfaces within to be biodecontaminated, typically, via hydrogen peroxide vapor or mist.

Cover Illustration by Katja Yount

22 Heads or Tails: Statistical Methods for Interpreting Multiple Biological Indicator Results
Donald Eddington, PhD, Eddington and Bond Associates, Inc.

One of the main advantages of using an isolator for an aseptic processing application is that it creates a physical separation between the operator and the aseptic workspace. Another main advantage is that an isolator can be completely sealed before aseptic work begins, allowing for the exposed interior surfaces within to be biodecontaminated, typically, via hydrogen peroxide vapor or mist.

Cover Illustration by Katja Yount

Departments

News & Notes
6 An Election Worthy of Your Vote
7 PDA Ed. Offering FDA Sterilization and Media Fills Training

People
8 Volunteer Spotlight: Lee Leichter
10 Chapter Update: PDA’s Southern California Chapter Gives Back
12 Photostream: PDA Europe 1st Annual Meeting; ATMPs and Viral Safety of ATMPs
14 Eye on Education: Training Critical to Safety of Sterilized Filters

Science
16 Science Snapshot: PDA’s LER Task Force Holds its First Workshop
19 Technology Column: Still Room for Improvement in Glass Packaging

Regulation
34 PDA Comments: Clarification Sought on Biologics Licensing Guidance
37 Outsourcing: Ensuring a Successful Relationship
38 Pharma Supply Chain Faces New GDPs, Reg Requirements
39 A Comparison of Microbial Environmental Limits

Voices of PDA
44 Voices of the Board: Microbiology: A Critical Focus Area for Strategic Plan
46 Editor’s Message: Dog Days of Summer End, Busy PDA Season Begins
28 A QbD Approach to Mitigating Risk in Prefilled Syringes
Fran DeGrazio, West Pharmaceutical Services

Over the past several years, we have seen a steady shift in the pharmaceutical industry toward an even more patient-centric approach related to the development of prefilled components. Nearly every aspect of the industry—from drug discovery to regulatory guidance, trial design and drug delivery system—is focused on developing new approaches to put patients first. The impact of this shift can be seen in the types of many new drugs proliferating the pipeline—namely cutting-edge biologics.

32 Visible Particulate Matter in Injectable Drug Products
Learn about the nature of visible particulate matter in parenteral products and its effects in this issue’s infographic.

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.
22 Heads or Tails: Statistical Methods for Interpreting Multiple Biological Indicator Results
Donald Eddington, PhD, Eddington and Bond Associates, Inc.

One of the main advantages of using an isolator for an aseptic processing application is that it creates a physical separation between the operator and the aseptic workspace. Another main advantage is that an isolator can be completely sealed before aseptic work begins, allowing for the exposed interior surfaces within to be biodecontaminated, typically, via hydrogen peroxide vapor or mist.

Cover Illustration by Katja Yount

News & Notes
6 An Election Worthy of Your Vote
7 PDA Ed. Offering FDA Sterilization and Media Fills Training

People
8 Volunteer Spotlight: Lee Leichter
10 Chapter Update: PDA’s Southern California Chapter Gives Back
12 Photostream: PDA Europe 1st Annual Meeting; ATMPs and Viral Safety of ATMPs
14 Eye on Education: Training Critical to Safety of Sterilized Filters

Science
16 Science Snapshot: PDA’s LER Task Force Holds its First Workshop
19 Technology Column: Still Room for Improvement in Glass Packaging

Regulation
34 PDA Comments: Clarification Sought on Biologics Licensing Guidance
37 Outsourcing: Ensuring a Successful Relationship
38 Pharma Supply Chain Faces New GDPs, Reg Requirements
39 A Comparison of Microbial Environmental Limits

Voices of PDA
44 Voices of the Board: Microbiology: A Critical Focus Area for Strategic Plan
46 Editor’s Message: Dog Days of Summer End, Busy PDA Season Begins
28  A QbD Approach to Mitigating Risk in Prefilled Syringes
Fran DeGrazio, West Pharmaceutical Services

Over the past several years, we have seen a steady shift in the pharmaceutical industry toward an even more patient-centric approach related to the development of prefilled components. Nearly every aspect of the industry—from drug discovery to regulatory guidance, trial design and drug delivery system—is focused on developing new approaches to put patients first. The impact of this shift can be seen in the types of many new drugs proliferating the pipeline—namely cutting-edge biologics.

32  Visible Particulate Matter in Injectable Drug Products
Learn about the nature of visible particulate matter in parenteral products and its effects in this issue’s infographic.
Cover

The Role of a Person in Plant for Early Development Projects
One Company’s Experience
Xiaona Jing, Jesper Valbjørn, Pernille Hemmingsen, Christian Cimander

Trust is important in any relationship, particularly the relationship between a sponsor company and a contract manufacturing organization (CMO). As outsourcing becomes more and more important in the strategic supply chain in the biopharmaceutical industry today, the effective management of the contract manufacture organizations (CMOs) is a topic of high interest. Many of the pioneers from both the customer and CMO sides gathered at the PDA Outsourcing/Contract Manufacturing conference in 2014 to discuss "Is outsourcing your weakest link?"
Microbiologists: Get to Know Manufacturing’s Raw Material Suppliers
Christine Massaro, Johnson & Johnson

It seems that as a whole, the relationship between microbiologists and our suppliers is backward. Instead of developing a consistent relationship complete with constant communication, most of us microbiologists only contact our raw material suppliers when a catastrophic problem arises, such as an out-of-specification (OOS) result.

Common CMO Audit Allergens

Audits of a contract manufacturing organization (CMO) are stressful for everyone. There are a number of common “allergens,” impacting both the auditor and the host company. But there are some Rx available to prevent these allergens.
Four Global Pharma Concerns in an Expanding World

Kelly Waldron, Dublin Institute of Technology (DIT) and Sanofi

Globalization of the pharmaceutical, biopharmaceutical, and medical device industries offers numerous benefits, but brings with it increased complexity. Seasoned industry practitioners can attest to this evolution, as evidenced by new challenges in navigating the international regulatory climate, the intricate nature of the supply chain, and an increase in the number/diversity of patients reached.
Contents

Features

38 Latin America: Moving from Importer to Exporter
Luis Caveda, PharmaBioServ
The Latin American pharma industry has traditionally been an importer of medicinal products, unable to generate revenue through exporting drugs or medical devices.

40 How Global Orgs Can Achieve Process Validation Success
Ajay Pazhayattil, Apotex Inc.
The pharmaceutical market has transformed into a global industry within just a few decades. Many companies have sites across the globe, presenting challenges when it comes to harmonizing process validation approaches.

44 PDA Member Reports from the 2016 PDA/FDA Joint Regulatory Conference
Missed this year’s PDA/FDA Joint Regulatory Conference? Find out what happened from three attendees who reported on the sessions.

46 PDA Then and Now
Nov. 18 marks PDA’s 70th anniversary. In light of this momentous occasion, the PDA Letter wanted to highlight significant milestones in PDA’s history, and compare where we were then to where we are today.

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.

PDA’s Mission
To develop scientifically sound, practical technical information and resources to advance science and regulation for the pharmaceutical and biopharmaceutical industry through the expertise of our global membership

PDA’s Vision
To be the foremost global provider of science, technology, and regulatory information and education for the pharmaceutical and biopharmaceutical community

Executive Staff

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Company/Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>President</td>
<td>Richard Johnson</td>
<td></td>
</tr>
<tr>
<td>Sr. VP, Education</td>
<td>Craig Elliott</td>
<td></td>
</tr>
<tr>
<td>VP, Finance</td>
<td>Jennifer Bell</td>
<td></td>
</tr>
<tr>
<td>VP, Sales</td>
<td>David Hall</td>
<td></td>
</tr>
<tr>
<td>Sr. VP, Scientific &amp; Regulatory Affairs</td>
<td>Rich Levy, PhD</td>
<td></td>
</tr>
<tr>
<td>Sr. VP, PDA Europe</td>
<td>Georg Roessling, PhD</td>
<td></td>
</tr>
</tbody>
</table>

PDA Board of Directors

Officers

Chair: Martin VanTrieste
Chair-Elect: Rebecca Devine, PhD Regulatory Consultant
Treasurer: Michael Sadowski, Baxter Healthcare
Secretary: Jette Christensen, Novo Nordisk
Imm. Past Chair: Harold Baseman ValSource

Directors

Masahiro Akimoto, Otsuka Pharmaceutical Factory, Inc.
Joyce Bloomfield
Veronique Davoust, Pfizer
Stephan Rönninger, Amgen
Susan Schniepp, Regulatory Compliance Associates
Glenn Wright, Eli Lilly and Company
Joyce Bloomfield
Ursula Busse, PhD Novartis
Emma Ramnarine, Genentech/Roche
Anil Sawant, Merck
Melissa Seymour, Biogen
Deborah M. Autor, Mylan

Articles published in the PDA Letter do not represent the official positions of PDA, Inc., but are the opinions of the authors submitting the articles.